AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and W
Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizer’s once-daily oral therapy Velsipity, after NICE recommended its use
Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.
Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described
GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 w